Hyperkalemia Clinical Trial
Official title:
Is Levalbuterol an Effective Treatment With Less Cardiac Side Effects Than Albuterol in Hyperkalemia Patients: A Randomized-controlled Clinical Trial Protocol.
Hyperkalemia is a common life-threatening electrolyte disturbance which may impair cardiac and many other organs' functions. Unfortunately, a well-established guideline for the treatment of hyperkalemia in the emergency setting is still missing. However, the last "Kidney Disease: Improving Global Outcomes (KDIGO)" conference proposed a treatment protocol for hyperkalemia and addressed controversies in this matter. Beta2-agonists were one of the main lines in the approach towards managing a patient with hyperkalemia. However, this evidence was only available for racemic albuterol. Levalbuterol is the isolated R-enantiomer of racemic albuterol which is comprised of S- and R-enantiomers. Several lab and clinical studies have assessed the effect, affinity, and selectivity of each of the enantiomers. Few studies in medical literature have compared the difference between these two drugs regarding cardiac effects with inconclusive results, and even fewer studies have compared the efficacies of these two drugs regarding potassium lowering effect. To the investigators' knowledge, no study to date has compared the efficacy and safety of albuterol compared to levalbuterol in hyperkalemic patients with the properly adjusted dosing. So, in clinical practice, the investigators wanted to know based on evidence if levalbuterol can be an effective substitute for albuterol in lowering potassium levels in hyperkalemia patients while yielding fewer cardiac side effects. To answer this question, the investigators designed a single-centered controlled clinical trial that includes adult hyperkalemia patients in Aleppo University Hospital.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03172702 -
Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia
|
Phase 3 | |
| Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
| Recruiting |
NCT05766839 -
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
|
Phase 2 | |
| Completed |
NCT02609841 -
POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study
|
N/A | |
| Recruiting |
NCT06277128 -
A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.
|
Phase 2 | |
| Recruiting |
NCT04789239 -
OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure
|
Phase 2 | |
| Completed |
NCT05029310 -
Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients
|
Phase 4 | |
| Terminated |
NCT04443608 -
Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
|
Phase 4 | |
| Completed |
NCT02607085 -
REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study
|
N/A | |
| Completed |
NCT03283267 -
A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)
|
Phase 1 | |
| Recruiting |
NCT06036823 -
5 Versus 10 Units of Insulin in Hyperkalemia Management
|
Phase 4 | |
| Completed |
NCT05184998 -
Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels
|
||
| Completed |
NCT01737697 -
Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia
|
Phase 3 | |
| Completed |
NCT01493024 -
Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia
|
Phase 2 | |
| Completed |
NCT04207203 -
Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study
|
N/A | |
| Completed |
NCT05382988 -
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
|
Phase 3 | |
| Completed |
NCT04217590 -
Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
|
Phase 3 | |
| Recruiting |
NCT03096561 -
Measurement of Serum Potassium Rate During Accidental Hypothermia.
|
N/A | |
| Completed |
NCT03326583 -
The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia
|
Phase 2 | |
| Completed |
NCT03528681 -
A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.
|
Phase 3 |